AbbVie disclosed that Class II director Jennifer L. Davis intends to resign from its Board of Directors, effective November 2, 2026, after her recent appointment as Chief Executive Officer at Align Technology, Inc. The filing states her resignation is not the result of any disagreement with AbbVie on its operations, policies or practices. The change is a board composition update with no financial figures attached.
Jennifer L. Davis, a Class II director, notified the Board on October 28, 2026 of her intent to resign.
Resignation is effective November 2, 2026.
Reason given: her recent appointment as Chief Executive Officer at Align Technology, Inc.
The filing states there was no dispute or disagreement with AbbVie on its operations, policies or practices.
AbbVie announced third-quarter 2026 net revenues of $17.404 billion and diluted EPS of $2.37 on a GAAP basis. The company raised its full-year 2026 adjusted diluted EPS guidance range to $13.95 through $13.99 and increased its quarterly cash dividend by 5.2 percent to $1.82 per share.
Third-quarter net revenues reached $17.404 billion, representing a 10.3 percent increase on a reported basis.
GAAP diluted EPS was $2.37, while adjusted diluted EPS was $3.82 for the third quarter ended September 30, 2026.
Full-year 2026 adjusted diluted EPS guidance was raised to a range of $13.95 to $13.99.
The quarterly cash dividend was increased by 5.2 percent to $1.82 per share, payable on February 16, 2027.
AbbVie expanded its Board of Directors from twelve to thirteen seats on October 14, 2026, and appointed Dr. John M. Carethers as a Class II director. The Board determined he is independent under NYSE standards, and he joins the Public Policy and Sustainability Committee.
Board size increased from twelve directors to thirteen on October 14, 2026
Dr. John M. Carethers appointed as Class II director; serves as Vice Chancellor for Health Sciences at UC San Diego
Carethers named to the Public Policy and Sustainability Committee and deemed independent under NYSE rules
Compensation as an independent director is disclosed in Exhibit 10.5 to the Form 10-Q for the quarter ended March 31, 2025
AbbVie said third-quarter 2026 results will include $216 million in pre-tax acquired IPR&D and milestones expense, which reduces both GAAP and adjusted diluted EPS by $0.11. The company lowered its guidance accordingly: full-year 2026 adjusted diluted EPS is now $13.76-$13.96, and third-quarter adjusted diluted EPS is $3.73-$3.77. Third-quarter figures are preliminary and have not been finalized.
Q3 2026 acquired IPR&D and milestones expense: $216 million pre-tax, a $0.11 per-share hit to GAAP and adjusted EPS
Full-year 2026 adjusted diluted EPS guidance: $13.76-$13.96, down from $13.87-$14.07 before the Q3 charge
Q3 2026 adjusted diluted EPS guidance: $3.73-$3.77, down from $3.84-$3.88 before the charge
Results for the quarter ended September 30, 2026 remain subject to closing procedures and may differ from these estimates
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
